128 related articles for article (PubMed ID: 27574017)
21. Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.
García-García C; Ibrahim YH; Serra V; Calvo MT; Guzmán M; Grueso J; Aura C; Pérez J; Jessen K; Liu Y; Rommel C; Tabernero J; Baselga J; Scaltriti M
Clin Cancer Res; 2012 May; 18(9):2603-12. PubMed ID: 22407832
[TBL] [Abstract][Full Text] [Related]
22. Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation.
Luo J; Pi G; Xiao H; Ye Y; Li Q; Zhao L; Huang H; Luo H; Zhang Q; Wang D; Wang G
Mol Med Rep; 2018 Jan; 17(1):366-373. PubMed ID: 29115478
[TBL] [Abstract][Full Text] [Related]
23. MLN0128, an ATP-competitive mTOR kinase inhibitor with potent in vitro and in vivo antitumor activity, as potential therapy for bone and soft-tissue sarcoma.
Slotkin EK; Patwardhan PP; Vasudeva SD; de Stanchina E; Tap WD; Schwartz GK
Mol Cancer Ther; 2015 Feb; 14(2):395-406. PubMed ID: 25519700
[TBL] [Abstract][Full Text] [Related]
24. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
25. Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
Hassan B; Akcakanat A; Sangai T; Evans KW; Adkins F; Eterovic AK; Zhao H; Chen K; Chen H; Do KA; Xie SM; Holder AM; Naing A; Mills GB; Meric-Bernstam F
Oncotarget; 2014 Sep; 5(18):8544-57. PubMed ID: 25261369
[TBL] [Abstract][Full Text] [Related]
26. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
27. Targeting of mTOR catalytic site inhibits multiple steps of the HIV-1 lifecycle and suppresses HIV-1 viremia in humanized mice.
Heredia A; Le N; Gartenhaus RB; Sausville E; Medina-Moreno S; Zapata JC; Davis C; Gallo RC; Redfield RR
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):9412-7. PubMed ID: 26170311
[TBL] [Abstract][Full Text] [Related]
28. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
29. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall BA; Kim TY; Skor MN; Conzen SD
Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
[TBL] [Abstract][Full Text] [Related]
31. A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models.
Zhang H; Berel D; Wang Y; Li P; Bhowmick NA; Figlin RA; Kim HL
PLoS One; 2013; 8(1):e54918. PubMed ID: 23349989
[TBL] [Abstract][Full Text] [Related]
32. A critical role for the mTORC2 pathway in lung fibrosis.
Chang W; Wei K; Ho L; Berry GJ; Jacobs SS; Chang CH; Rosen GD
PLoS One; 2014; 9(8):e106155. PubMed ID: 25162417
[TBL] [Abstract][Full Text] [Related]
33. Radiosensitization of clioquinol and zinc in human cancer cell lines.
Lu S; Ke Y; Wu C; Zhong Y; Xie C; Zhou Y; Zhou F; Yu H
BMC Cancer; 2018 Apr; 18(1):448. PubMed ID: 29678153
[TBL] [Abstract][Full Text] [Related]
34. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
35. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro.
Wang WJ; Long LM; Yang N; Zhang QQ; Ji WJ; Zhao JH; Qin ZH; Wang Z; Chen G; Liang ZQ
Acta Pharmacol Sin; 2013 May; 34(5):681-90. PubMed ID: 23603977
[TBL] [Abstract][Full Text] [Related]
36. Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor is an effective radiosensitizer for colorectal cancer.
Chen YH; Wei MF; Wang CW; Lee HW; Pan SL; Gao M; Kuo SH; Cheng AL; Teng CM
Cancer Lett; 2015 Feb; 357(2):582-90. PubMed ID: 25497009
[TBL] [Abstract][Full Text] [Related]
37. Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy.
Chen X; Díaz-Rodríguez E; Ocio EM; Paiva B; Mortensen DS; Lopez-Girona A; Chopra R; Miguel JS; Pandiella A
Mol Cancer Ther; 2014 Feb; 13(2):504-16. PubMed ID: 24431075
[TBL] [Abstract][Full Text] [Related]
38. The TORC1/2 inhibitor TAK228 sensitizes atypical teratoid rhabdoid tumors to cisplatin-induced cytotoxicity.
Rubens JA; Wang SZ; Price A; Weingart MF; Allen SJ; Orr BA; Eberhart CG; Raabe EH
Neuro Oncol; 2017 Oct; 19(10):1361-1371. PubMed ID: 28582547
[TBL] [Abstract][Full Text] [Related]
39. mTOR regulates NLRP3 inflammasome activation via reactive oxygen species in murine lupus.
Li X; Zhang X; Pan Y; Shi G; Ren J; Fan H; Dou H; Hou Y
Acta Biochim Biophys Sin (Shanghai); 2018 Sep; 50(9):888-896. PubMed ID: 30060081
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of Hsp90 and mTOR inhibitors as potential drugs for the treatment of TSC1/TSC2 deficient cancer.
Mrozek EM; Bajaj V; Guo Y; Malinowska IA; Zhang J; Kwiatkowski DJ
PLoS One; 2021; 16(4):e0248380. PubMed ID: 33891611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]